# First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer

Source: https://onco.cc/trials/nct07756281/  
OnCo record `nct07756281` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is not yet recruiting.

## Summary

The registry lists NCT07756281 as not yet recruiting, last updated 2026-08-10. Enrolment is 40 planned participants, an estimate. Interventions: SNV1521, daraxonrasib. Primary measures include Safety and tolerability of SNV1521 plus daraxonrasib: treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities. No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-10-06
- Registry id: NCT07756281
- Phase: 1
- Setting: A Phase 1, Open-Label, Dose-Escalation and Expansion Study of SNV1521 in Combination With RAS Inhibition in Participants With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
- Sponsor: Synnovation Therapeutics, Inc.

## Sources

- ClinicalTrials.gov NCT07756281: https://clinicaltrials.gov/study/NCT07756281

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [SNV1521](https://onco.cc/drugs/snv1521/)

---
JSON: https://onco.cc/api/v1/entities/nct07756281.json